Literature DB >> 28653297

Adherence of psychopharmacological prescriptions to clinical practice guidelines in patients with eating behavior disorders.

María Del Mar Alañón Pardo1, Mónica Ferrit Martín2, Miguel Ángel Calleja Hernández3, Francisco Morillas Márquez4.   

Abstract

PURPOSE: The purpose of this study was to analyze the adherence of psychopharmacological prescriptions to clinical practice guidelines (CPGs) for patients with eating behavior disorders (EDs) and to compare the effectiveness, safety, and cost of treatment according to adherence.
METHODS: This retrospective observational study included ED patients admitted to the eating disorders unit (EDU) of Ciudad Real Hospital (Spain) between January 2006 and December 2009 and followed until December 2014. Psychopharmaceuticals prescribed during EDU stay(s) were compared with guidelines published by American Psychiatric Association (APA), National Institute for Clinical Excellence (NICE), and Spanish Ministry of Health and Consumption (SMHC). Adherence was considered as the percentage of patients whose prescription followed all recommendations.
RESULTS: The study included 113 ED patients. Adherence to APA and NICE/SMHC was 30.1% and 45.1%, respectively. Weekly weight gain during hospital stay was higher (p = 0.037) in the APA "adherence" (807.6 g) versus "non-adherence" (544.4 g) group. An association was found between CPG adherence and higher 5-year full recovery rate (p < 0.040). Adherence to NICE/SMHC was associated with lower incidence (p = 0.001) of adverse effects (33.3% in adherence vs. 66.1% in non-adherence group). CPG adherence was associated with lower medication costs (p < 0.020). The age was higher and there was a greater frequency of self-harm behavior and psychiatric comorbidities in the non-adherence than adherence group (p ≤ 0.040).
CONCLUSIONS: CPG adherence was low in EDU-admitted patients. Long-term follow-up showed that clinical outcomes were better and medication costs lower in patients with versus without CPG-adherent prescriptions, likely influenced by the apparently greater severity of illness in those with non-CPG-adherent prescriptions.

Entities:  

Keywords:  Adherence-degree; Anorexia nervosa; Bulimia nervosa; Eating disorders; Guidelines; Psychopharmaceuticals

Mesh:

Substances:

Year:  2017        PMID: 28653297     DOI: 10.1007/s00228-017-2287-2

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

Review 1.  Behavioral management for anorexia nervosa.

Authors:  Evelyn Attia; B Timothy Walsh
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

2.  Association of general medical and psychiatric comorbidities with receipt of guideline-concordant care for depression.

Authors:  Susan L Ettner; Francisca Azocar; Robert B Branstrom; Lisa S Meredith; Lily Zhang; Michael K Ong
Journal:  Psychiatr Serv       Date:  2010-12       Impact factor: 3.084

3.  Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? Results from the Texas Medication Algorithm Project.

Authors:  Ellen B Dennehy; Trisha Suppes; A John Rush; Alexander L Miller; Madhukar H Trivedi; M Lynn Crismon; Thomas J Carmody; T Michael Kashner
Journal:  Psychol Med       Date:  2005-09-29       Impact factor: 7.723

Review 4.  Psychopharmacologic treatment of eating disorders: emerging findings.

Authors:  Susan L McElroy; Anna I Guerdjikova; Nicole Mori; Paul E Keck
Journal:  Curr Psychiatry Rep       Date:  2015-05       Impact factor: 5.285

5.  Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial.

Authors:  Cerstin Nickel; Karin Tritt; Moritz Muehlbacher; Francisco Pedrosa Gil; Ferdinand O Mitterlehner; Patrick Kaplan; Claas Lahmann; Peter K Leiberich; Jakub Krawczyk; Christian Kettler; Wolfhardt K Rother; Thomas H Loew; Marius K Nickel
Journal:  Int J Eat Disord       Date:  2005-12       Impact factor: 4.861

Review 6.  Psychotropic drug treatment in anorexia nervosa. Search for differences in efficacy/tolerability between adolescent and mixed-age population.

Authors:  Matteo Balestrieri; Maria Ginevra Oriani; Annalisa Simoncini; Cesario Bellantuono
Journal:  Eur Eat Disord Rev       Date:  2013-06-04

7.  An open trial of fluoxetine in patients with anorexia nervosa.

Authors:  W H Kaye; T E Weltzin; L K Hsu; C M Bulik
Journal:  J Clin Psychiatry       Date:  1991-11       Impact factor: 4.384

8.  Symptoms of depression and anxiety in anorexia nervosa: links with plasma tryptophan and serotonin metabolism.

Authors:  Claire Gauthier; Christine Hassler; Lama Mattar; Jean-Marie Launay; Jacques Callebert; Howard Steiger; Jean-Claude Melchior; Bruno Falissard; Sylvie Berthoz; Virginie Mourier-Soleillant; François Lang; Marc Delorme; Xavier Pommereau; Priscille Gerardin; Stephanie Bioulac; Manuel Bouvard; Nathalie Godart
Journal:  Psychoneuroendocrinology       Date:  2013-09-17       Impact factor: 4.905

Review 9.  Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management.

Authors:  Søren Fanoe; Diana Kristensen; Anders Fink-Jensen; Henrik Kjærulf Jensen; Egon Toft; Jimmi Nielsen; Poul Videbech; Steen Pehrson; Henning Bundgaard
Journal:  Eur Heart J       Date:  2014-03-18       Impact factor: 29.983

10.  Implementing clinical guidelines in psychiatry: a qualitative study of perceived facilitators and barriers.

Authors:  Tord Forsner; Johan Hansson; Mats Brommels; Anna Aberg Wistedt; Yvonne Forsell
Journal:  BMC Psychiatry       Date:  2010-01-20       Impact factor: 3.630

View more
  3 in total

Review 1.  Psychopharmacologic Management of Eating Disorders.

Authors:  Alexandra F Muratore; Evelyn Attia
Journal:  Curr Psychiatry Rep       Date:  2022-05-16       Impact factor: 8.081

Review 2.  Anorexia nervosa: Outpatient treatment and medical management.

Authors:  Stein Frostad; Mette Bentz
Journal:  World J Psychiatry       Date:  2022-04-19

Review 3.  Pharmacotherapeutic strategies for the treatment of anorexia nervosa - too much for one drug?

Authors:  Guido K W Frank
Journal:  Expert Opin Pharmacother       Date:  2020-04-13       Impact factor: 3.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.